2022
DOI: 10.3390/ph15101175
|View full text |Cite
|
Sign up to set email alerts
|

Partial Synthetic PPARƳ Derivative Ameliorates Aorta Injury in Experimental Diabetic Rats Mediated by Activation of miR-126-5p Pi3k/AKT/PDK 1/mTOR Expression

Abstract: Type 2 diabetes mellitus (T2D) is a world wild health care issue marked by insulin resistance, a risk factor for the metabolic disorder that exaggerates endothelial dysfunction, increasing the risk of cardiovascular complications. Peroxisome proliferator-activated receptor PPAR) agonists have therapeutically mitigated hyperlipidemia and hyperglycemia in T2D patients. Therefore, we aimed to experimentally investigate the efficacy of newly designed synthetic PPARα/Ƴ partial agonists on a High-Fat Diet (HFD)/stre… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 122 publications
0
1
0
Order By: Relevance
“…Additionally, apoptotic bodies released during endothelial apoptosis have been shown to contain miRNA-126, which attracts endothelial progenitor cells to the site and prevents arterial lesion development. 8,9) Furthermore, miRNA-126 has an anti-inflammatory effect on ECs, as transfection with miRNA-126 oligonucleotides has been shown to inhibit the expression of vascular adhesion molecule 1 (VCAM-1) stimulated by TNF-α and prevent leukocyte adhesion to ECs. 10) Therefore, identifying a drug that can regulate the expression of miRNA-126 offers more options for improving endothelial function, promoting endometrial repair and reendothelialization, and preventing the occurrence and development of ISR.…”
Section: Introductionmentioning
confidence: 99%
“…Additionally, apoptotic bodies released during endothelial apoptosis have been shown to contain miRNA-126, which attracts endothelial progenitor cells to the site and prevents arterial lesion development. 8,9) Furthermore, miRNA-126 has an anti-inflammatory effect on ECs, as transfection with miRNA-126 oligonucleotides has been shown to inhibit the expression of vascular adhesion molecule 1 (VCAM-1) stimulated by TNF-α and prevent leukocyte adhesion to ECs. 10) Therefore, identifying a drug that can regulate the expression of miRNA-126 offers more options for improving endothelial function, promoting endometrial repair and reendothelialization, and preventing the occurrence and development of ISR.…”
Section: Introductionmentioning
confidence: 99%